Review articleTherapeutic targets in idiopathic pulmonary fibrosis

•There are several targets for therapeutic intervention in the pathogenesis of IPF.•Two therapies have been approved for treatment of IPF: nintedanib and pirfenidone.•Several potential therapies for IPF are in investigation in Phase II trials.•Combination therapy will likely provide the most effective treatment for IPF.

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal interstitial lung disease. After many drugs failed in clinical trials, improvements in the understanding of the pathogenesis of IPF led to the approval of two drugs that slow the progression of the disease. However, the prognosis for patients with IPF remains poor and the search continues for drugs that inhibit the pathogenic pathways active in IPF to reduce or even halt the progression of the disease. In this article, we review the mechanisms of action of the two approved therapies for IPF (nintedanib and pirfenidone) and of the investigational compounds that are in Phase II trials and discuss the potential for combination therapy in the treatment of IPF.